Business Wire

Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D

Share

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021. On that date, Dr. Junichi Koga will retire from the position, after a successful and industrious career, including more than 12 years at Daiichi Sankyo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005290/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ken Takeshita, MD (Photo: Business Wire)

Dr. Takeshita joins Daiichi Sankyo from Kite Pharma, a Gilead Company, where he was Senior Vice President and Global Head of Development since 2019, and interim Head of Research. Ken is a highly experienced physician with deep experience in oncology and rare diseases. Prior to Kite, he served as Senior Vice President of Clinical Research at Sorrento Therapeutics and Corporate Vice President of Clinical R&D at Celgene. He has led full-scale global drug development programs across hematological and solid tumors at Kite, Celgene and Amgen. Before joining the biopharmaceutical industry, Ken was on the faculty in Hematology at Yale University School of Medicine and New York University School of Medicine. He earned a bachelor’s degree in molecular biology from Harvard University and his medical degree from Yale University. He received post-doctoral training in hematology, oncology and developmental biology at Yale and in hematopoiesis at University of Tokyo.

“We are thrilled to welcome Ken into the Daiichi Sankyo family to lead global R&D in our continued transformation into a global oncology leader and to pursue world-class science and technology,” said Sunao Manabe, President and CEO, Daiichi Sankyo Company, Ltd. “Ken brings remarkable depth and breadth of experience to our organization – from first-hand patient care to overseeing more than 20 registrational trials leading to many regulatory approvals. I am confident that Ken is the right leader to bring Daiichi Sankyo into our next phase of drug discovery and development, as we innovate and deliver practice-changing medicines to our global community.”

“I am honored to join the Daiichi Sankyo R&D organization to seek to extend and improve lives of patients and eliminate cancer altogether,” said Dr. Ken Takeshita. “I have watched Daiichi Sankyo build and grow with admiration. I look forward to bringing the Company’s antibody drug conjugates and new, innovative modalities to more patients and to working in a unique company culture with Japanese roots, fitting of a world-class global organization,” said Dr. Takeshita.

“Junichi has been instrumental in shaping our current R&D portfolio, particularly in spearheading the establishment of our biologics research organization, out of which our incredibly promising ADC pipeline was born,” said Dr. Manabe. “We thank him for his dedication to patients and to Daiichi Sankyo and look forward to continuing to work with him as an advisor to me and our leaders in 2021.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

US:
Kimberly Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 908 992 6633 (office)
+1 908 656 5447 (mobile)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

EU:
Nadine Paschen
Daiichi Sankyo Europe GmbH
Nadine.Paschen@daiichi-sankyo.eu
+49 89 780 8590

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stephen Stonberg appointed interim CEO of Bittrex Global17.5.2021 19:14:00 CEST | Press release

The Boards of Directors (the “Boards”) of Bittrex Global GmbH (Vaduz, Liechtenstein) and Bittrex Global (Bermuda) Ltd (Hamilton, Bermuda) have confirmed that Tom Albright is stepping down from his role as CEO of both companies effective today. The Boards are grateful for the contributions Tom has made. Stephen Stonberg, current CFO and COO of Bittrex Global, has been appointed by the Boards to serve as interim CEO, to oversee management of the Companies. “Tom has brought key leadership as Bittrex Global has grown to serve the crypto marketplace,” said Bill Shihara, Co-Founder Bittrex, Inc. “Tom has also helped guide the company through a period of significant growth and change within our sector”. “We are incredibly pleased that Stephen Stonberg will be leading Bittrex Global as interim CEO,” said Shihara. “Stephen has served as CFO and COO since February 2019, and has a deep understanding of our business, and has over 25 years experience in the financial services sector, and held leade

Lumen Metabolic Health Device Now Peer-reviewed17.5.2021 18:57:00 CEST | Press release

Lumen , a health tech company and the creators of the world's first portable metabolism measurement device, has officially been peer-reviewed and published in the Interactive Journal of Medical Research (I-JMR). In collaboration with San Francisco State University, Lumen has validated an ongoing study launched in 2020, which shows the validity of Lumen® to detect changes in metabolic fuel utilization in a comparable manner with a laboratory standard metabolic cart, providing the ability for real-time metabolic information for users under any circumstances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005774/en/ Lumen now peer-reviewed (Photo: Business Wire) Developed through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath. The methodology behind the peer-reviewed validation of Lumen The study compares the

Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 202217.5.2021 15:46:00 CEST | Press release

Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”). The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the

monday.com Announces Filing of Registration Statement for Proposed Initial Public Offering17.5.2021 14:45:00 CEST | Press release

monday.com Ltd. (“monday.com”), a work operating system (Work OS) where organizations of any size can create the tools and processes they need to manage every aspect of their work, announced today it has filed a registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. monday.com intends to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “MNDY.” Goldman Sachs & Co. LLC and J.P. Morgan will act as lead book-running managers for the proposed offering, with Allen & Company LLC and Jefferies acting as joint book-running managers. William Blair, Piper Sandler, Oppenheimer & Co., Canaccord Genuity, Cowen and Needham & Company will act as co-managers for the proposed offering. The offering will be made only by means of a prospectus. Copies of t

Personalis, Inc. to Present at Biomarkers Week Online 202117.5.2021 14:01:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021. The presentation, titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker discovery,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of the platform, which combines highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics to provide a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. Dr. Newburn will review a case study in a cohort of 51 late-stage melanoma patients that demonstrates how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other marker

Bentley and ESI Group Work Together to Refine the Flying Spur Through Sustainable Design Process17.5.2021 14:00:00 CEST | Press release

Regulatory News: ESI Group (Paris:ESI), a global player in virtual prototyping for industries, worked hand in hand with Bentley on the optimization of one of the world’s finest four door sedan, the Flying Spur. Thanks to virtual prototyping, teams have been able to eliminate noise, vibration and harshness (NVH) and reduces physical parts in test phase. Advanced virtual design processes have been used in the testing and production cycles of the third Flying Spur generation. Thanks to ESI’s virtual prototyping, a weight optimization program for the Flying Spur could be undertaken on 40 different components. The finely tuned process enabled acoustic tests for any airborne sounds filtering into the cabin to be completed, as well as any impact from the structure itself, such as tire noise. This ensured the correct soundproofing materials were deployed in the right locations around the vehicle, so passengers can enjoy the quietest cabin experience possible. These cutting-edge techniques are

Vecima Networks and Vector Technologies Enable Gigabit Services for Liberty Global17.5.2021 14:00:00 CEST | Press release

Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint. The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency. “The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom